Challenges and Future Directions in Globalization of Rasashastra Based Herbo - Mineral Drugs

Background: Rasa Shastra, the specialized branch of Ayurveda dealing with herbo-mineral formulations, holds a rich therapeutic legacy in India. The globalization of Rasa Shastra medicines faces significant scrutiny due to safety, toxicity concerns, and regulatory hurdles despite their potential in chronic, metabolic, and degenerative diseases. Objectives: To critically evaluate the key challenges in the globalization of Rasa Shastra based herbo-mineral drugs and to identify potential strategies and future research directions for their safe, effective, and sustainable global acceptance. Methods: A narrative review was conducted by analysing classical Ayurvedic texts, contemporary scientific studies, regulatory frameworks of different countries, and WHO guidelines on traditional medicines. Literature was sourced from PubMed, AYUSH databases, and policy documents, focusing on safety, standardization, regulatory barriers, and translational research. Results: The major challenges identified include: Lack of globally acceptable standardization and quality control protocols. Heavy metal toxicity concerns due to improper preparation and lack of Shodhana (purification) validation. Inadequate preclinical and clinical safety studies conforming to modern biomedical standards. Stringent international regulations and limited intellectual property protections. Poor awareness and misconceptions about Rasa Shastra among global medical communities. Future directions emphasize: Developing validated Shodhana protocols with toxicological evidence. Implementing GMP certified production and standardization techniques. Conducting multicentric clinical trials adhering to international norms. Engaging in cross-disciplinary research integrating Ayurveda, pharmacology, and nanotechnology. Establishing clear regulatory guidelines with the involvement of WHO and national authorities. Conclusion: Globalization of Rasa Shastra based herbo-mineral formulations is feasible with strategic interventions in safety validation, standardization, clinical evidence generation, and international collaborations. These efforts can pave the way for integrating Rasa Shastra therapeutics into global healthcare systems while ensuring safety, efficacy, and sustainability.